Table 3.

Percentage of responders, i.e., patients with 2-point decrease in visual analog scale pain severity at each efficacy timepoint.

Group	2-month Proportion (95% CI)	3-month Proportion (95% CI)	4-month Proportion (95% CI)
IA-BoNT/A	71 (49, 92)	62 (41, 83)	50 (27, 73)
IA-placebo	35 (15, 54)	43 (22, 64)	55 (33, 77)
Difference (IA-BoNT/A–IA-placebo)*	36 (7, 65)	19 (−11, 49)	−5 (−37, 27)

^*The difference between botulinum toxin and placebo groups was statistically significant at 2 months (p = 0.025). The difference between botulinum toxin and placebo groups was also statistically significant when all 3 timepoints (2, 3 and 4 months) were included (p = 0.019), using generalized estimating equations analyses.